Aurlide

Executive Summary

Aurlide is a Finnish biotechnology company established in 2018 that specializes in small molecule drug discovery services. The company leverages its proprietary virtual high-throughput screening (vHTS) platform to assist clients in identifying and optimizing first-in-class hit molecules, spanning target validation through lead optimization. By integrating computational screening with experimental validation, Aurlide aims to accelerate early-stage drug discovery and reduce failure risks for its partners. Operating at the pre-clinical stage, the company has not disclosed funding rounds or valuation, indicating it may be bootstrapped or in early incubation. With a focus on service-based revenue rather than proprietary pipelines, Aurlide's business model relies on establishing collaborations with biopharma firms seeking efficient hit discovery. The company's location in Turku, Finland, positions it within a growing Nordic biotech ecosystem, though its impact remains niche. Given the lack of public milestones, Aurlide's near-term trajectory hinges on securing partnership contracts and demonstrating the reliability of its vHTS platform in real-world drug discovery projects.

Upcoming Catalysts (preview)

• Q2 2027Announcement of first major partnership or service contract with a pharmaceutical or biotech company60% success
• Q3 2026Publication of a case study or validation data demonstrating successful hit identification via vHTS platform70% success
• Q4 2026Securing seed or Series A funding from investors to expand platform capabilities and sales team40% success